Arcus Biosciences (RCUS) Institutional Ownership
13F filers reported holding 28.6% of Arcus Biosciences (RCUS) shares as of Sep 30, 2026, across 92 filers.
- Held by 13F filers
- 28.6%
- Sep 30, 2026
- 13F filers
- 92
- quarter ended Sep 30, 2026
- 13F value
- $1.1B
- 41.2M shares
- Quarter's fund flow
- Mild accumulation
- 12 new · 7 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Azoy Alexander | Chief Accounting Officer | Acquired · Option exercise | 2,827 | $15.44 | ↗ |
| Aug 21, 2026 | Azoy Alexander | Chief Accounting Officer | Disposed · Open-market sale | 2,827 | $30.00 | ↗ |
| Aug 21, 2026 | Azoy Alexander | Chief Accounting Officer | Disposed · Option exercise | 2,827Stock Option (right to buy) | — | ↗ |
| Jul 10, 2026 | Jaen Juan C. | President | Disposed · Open-market sale | 19,799 | $28.61 | ↗ |
| Jul 10, 2026 | Jaen Juan C. | President | Disposed · Open-market sale | 268 | $29.40 | ↗ |
| Jul 9, 2026 | Jaen Juan C. | President | Disposed · Open-market sale | 48,502 | $30.05 | ↗ |
| Jun 24, 2026 | Jaen Juan C. | President | Disposed · Open-market sale | 6,431 | $29.66 | ↗ |
| Jun 23, 2026 | Jaen Juan C. | President | Disposed · Open-market sale | 14,067 | $27.69 | ↗ |
| Jun 23, 2026 | Jaen Juan C. | President | Disposed · Open-market sale | 1,697 | $28.06 | ↗ |
| Jun 22, 2026 | Jaen Juan C. | President | Disposed · Open-market sale | 9,236 | $27.03 | ↗ |
| Jun 11, 2026 | Tang Carolyn C. | General Counsel | Acquired · Option exercise | 34,090 | $2.57 | ↗ |
| Jun 11, 2026 | Tang Carolyn C. | General Counsel | Disposed · Option exercise | 34,090Stock Option (Right to Buy) | $2.57 | ↗ |
| Jun 11, 2026 | Ribas Antoni | director | Acquired · Grant / award | 5,700 | — | ↗ |
| Jun 11, 2026 | Ribas Antoni | director | Acquired · Grant / award | 16,900Stock Option (Right to Buy) | — | ↗ |
| Jun 11, 2026 | Lambert Nicole | director | Acquired · Grant / award | 5,700 | — | ↗ |
| Jun 11, 2026 | Lambert Nicole | director | Acquired · Grant / award | 16,900Stock Option (Right to Buy) | — | ↗ |
| Jun 11, 2026 | Lacey David L. | director | Acquired · Grant / award | 5,700 | — | ↗ |
| Jun 11, 2026 | Lacey David L. | director | Acquired · Grant / award | 16,900Stock Option (Right to Buy) | — | ↗ |
| Jun 11, 2026 | Machado Patrick | director | Acquired · Grant / award | 5,700 | — | ↗ |
| Jun 11, 2026 | Machado Patrick | director | Acquired · Grant / award | 16,900Stock Option (Right to Buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Arcus Biosciences do institutions hold?
13F filers reported holding 28.6% of Arcus Biosciences' shares as of Sep 30, 2026, across 92 filers.
How many 13F filers hold Arcus Biosciences?
Arcus Biosciences was held by 92 13F filers as of Sep 30, 2026.
Not investment advice.

